SCHEMBL317103

SCHEMBL317103

CCCC[Sn](/C=C/CO)(CCCC)CCCC

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
PPARG P37231 5/20 0.31
PPARD Q03181 4/20 0.31
PPARA Q07869 4/20 0.31
LMNA P02545 4/20 0.31
F7 P08709 4/20 0.31
F3 P13726 4/20 0.31
FFAR1 O14842 3/20 0.31
HSD17B10 Q99714 3/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP19A1 P11511 2/20 0.31
FABP4 P15090 2/20 0.31
HPGD P15428 2/20 0.31
ALOX15 P16050 2/20 0.31
NR4A2 P43354 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434976 1.00 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2PPARGPPARDPPARA
SCHEMBL317104 1.00 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2PPARGPPARDPPARA
SCHEMBL23391756 0.85 FASN (0.32)
SCHEMBL7087446 0.85 FASN (0.32)
SCHEMBL7087442 0.85 FASN (0.32)
SCHEMBL3784841 0.82 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2PPARGPPARDPPARA
SCHEMBL3784843 0.82 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2PPARGPPARDPPARA
SCHEMBL4115693 0.82 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2PPARGPPARDPPARA
SCHEMBL3788506 0.80 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2PPARGPPARDPPARA
SCHEMBL29080445 0.80 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388755-A1 PROBE FOR DETECTING CARBAPENEM-RESISTANT BACTERIA AND USE THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2025-12-25 US disclosed
US-12421393-B2 Probe for detecting carbapenem-resistant bacteria and use thereof INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2025-09-23 US disclosed
US-11465997-B2 Synthesis of disorazoles and analogs thereof as potent anticancer agents WILLIAM MARSH RICE UNIVERSITY (US) 2022-10-11 US disclosed
US-20210277246-A1 PROBE FOR DETECTING CARBAPENEM-RESISTANT BACTERIA AND USE THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2021-09-09 US disclosed
US-20210155616-A1 SYNTHESIS OF DISORAZOLES AND ANALOGS THEREOF AS POTENT ANTICANCER AGENTS WILLIAM MARSH RICE UNIVERSITY (US) 2021-05-27 US disclosed
WO-2020027553-A1 PROBE FOR DETECTING CARBAPENEM-RESISTANT BACTERIA AND USE THEREOF 한양대학교 에리카산학협력단 2020-02-06 WO disclosed
EP-2081903-B1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-05-07 EP disclosed
US-8664203-B2 Thiazole derivatives and their use as P2Y12 receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-04 US disclosed
US-20130315825-A1 TRICYCLIC HETEROAROMATIC COMPOUNDS AS ALPHA-SYNUCLEIN LIGANDS WASHINGTON UNIVERSITY (US) 2013-11-28 US disclosed
US-20130281406-A2 THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2013-10-24 US disclosed
WO-2001021596-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2001-03-29 WO disclosed
US-6140340-A FOR TREATING FUNGAL INFECTIONS HOECHST MARION ROUSSEL (FR) 2000-10-31 US disclosed
WO-2000020413-A1 NOVEL 2-[3-PHENYL-2-PROPENYL]-1,2,3,4-TETRAHYDROXYISOQUINOLINE DERIVATIVES, PREPARATION METHOD AND USE AS FUNGICIDES AVENTIS PHARMA S.A. (FR) 2000-04-13 WO disclosed
EP-0992502-A1 2-(3-Phenyl-2-propenyl)-1,2,3,4-tetrahydro-isochinolin derivatives, process for their preparation and their use as fungicides HOECHST MARION ROUSSEL (FR) 2000-04-12 EP disclosed
US-5840859-A (Aminostyryl)pyridinium compounds for radiolabelling cell membranes RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-11-24 US disclosed
EP-0629604-B1 Alicyclic phospholipase A2 inhibitors BRISTOL MYERS SQUIBB CO (US) 1997-04-16 EP disclosed
EP-0691343-A1 CEPHALOSPORIN DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-01-10 EP disclosed
US-5436369-A Alicyclic phospholipase A2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-25 US disclosed
EP-0629604-A2 Alicyclic phospholipase A2 inhibitors Bristol-Myers Company (US) 1994-12-21 EP disclosed
US-5216015-A Androstanes RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388755-A1 PROBE FOR DETECTING CARBAPENEM-RESISTANT BACTERIA AND USE THEREOF KLK3, SI, KLK1 ALDH1A1 660/4885SMN1; SMN2 2877/4885PPARG 4866/4885
US-12421393-B2 Probe for detecting carbapenem-resistant bacteria and use thereof ABCC1, MGAM, PGLS ALDH1A1 324/4885SMN1; SMN2 4077/4885PPARG 4845/4885
US-20130315825-A1 TRICYCLIC HETEROAROMATIC COMPOUNDS AS ALPHA-SYNUCLEIN LIGANDS SNCA, PARK7, HTT ALDH1A1 3495/4885SMN1; SMN2 533/4885PPARG 570/4885
US-11465997-B2 Synthesis of disorazoles and analogs thereof as potent anticancer agents CD47, DUT, CD99 ALDH1A1 202/4885SMN1; SMN2 3938/4885PPARG 4159/4885
US-20130281406-A2 THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS P2RY12, P2RY1, P2RY2 ALDH1A1 614/4885SMN1; SMN2 3642/4885PPARG 260/4885
US-20210155616-A1 SYNTHESIS OF DISORAZOLES AND ANALOGS THEREOF AS POTENT ANTICANCER AGENTS CD47, DUT, CD99 ALDH1A1 202/4885SMN1; SMN2 3938/4885PPARG 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.